O	0	8	Efficacy
O	9	12	and
O	13	19	safety
O	20	22	of
B-intervention	23	26	RGB
I-intervention	26	27	-
I-intervention	27	29	02
O	29	30	,
O	31	32	a
O	33	46	pegfilgrastim
O	47	57	biosimilar
O	58	60	to
O	61	68	prevent
B-condition	69	81	chemotherapy
I-condition	81	82	-
I-condition	82	89	induced
I-condition	90	101	neutropenia
O	101	102	:
O	103	110	results
O	111	113	of
O	114	115	a
O	116	126	randomized
O	126	127	,
O	128	134	double
O	134	135	-
O	135	140	blind
O	141	146	phase
O	147	150	III
O	151	159	clinical
O	160	165	study
O	166	168	vs
O	168	169	.
O	170	179	reference
O	180	193	pegfilgrastim
O	194	196	in
O	197	205	patients
O	206	210	with
O	211	217	breast
O	218	224	cancer
O	225	234	receiving
O	235	247	chemotherapy
O	247	248	.

O	249	258	Treatment
O	259	263	with
O	264	275	recombinant
O	276	281	human
O	282	293	granulocyte
O	293	294	-
O	294	300	colony
O	301	312	stimulating
O	313	319	factor
O	320	321	(
O	321	322	G
O	322	323	-
O	323	326	CSF
O	326	327	)
O	328	330	is
O	331	339	accepted
O	340	348	standard
O	349	352	for
O	353	363	prevention
O	364	366	of
O	367	379	chemotherapy
O	379	380	-
O	380	387	induced
O	388	399	neutropenia
O	399	400	.

O	401	404	RGB
O	404	405	-
O	405	407	02
O	408	409	(
O	409	415	Gedeon
O	416	423	Richter
O	423	424	)
O	425	427	is
O	428	429	a
O	430	438	proposed
O	439	449	biosimilar
O	450	452	to
O	453	462	pegylated
O	463	464	G
O	464	465	-
O	465	468	CSF
O	469	470	(
O	470	478	Neulasta
O	478	479	®
O	479	480	,
O	481	486	Amgen
O	486	487	)
O	488	492	with
O	493	502	sustained
O	503	510	release
O	511	521	properties
O	521	522	.

O	523	527	This
O	528	530	is
O	531	532	a
O	533	543	randomized
O	543	544	,
O	545	556	comparative
O	556	557	,
O	558	564	double
O	564	565	-
O	565	570	blind
O	570	571	,
O	572	583	multicenter
O	584	589	study
O	590	592	to
O	593	601	evaluate
O	602	610	efficacy
O	611	614	and
O	615	621	safety
O	622	624	of
O	625	628	RGB
O	628	629	-
O	629	631	02
O	632	634	in
B-eligibility	635	641	breast
I-eligibility	642	648	cancer
I-eligibility	649	657	patients
I-eligibility	658	667	receiving
I-eligibility	668	677	cytotoxic
I-eligibility	678	685	regimen
O	685	686	.

B-total-participants	687	690	Two
I-total-participants	691	698	hundred
I-total-participants	699	705	thirty
I-total-participants	705	706	-
I-total-participants	706	710	nine
O	711	716	women
O	717	727	presenting
O	728	732	with
O	733	739	breast
O	740	746	cancer
O	747	751	were
O	752	762	randomized
O	763	765	to
O	766	769	RGB
O	769	770	-
O	770	772	02
O	773	774	(
O	774	775	n
O	776	777	=
B-intervention-participants	778	781	121
O	781	782	)
O	783	786	and
O	787	790	the
B-control	791	800	reference
I-control	801	808	product
O	809	810	(
O	810	811	n
O	812	813	=
B-control-participants	814	817	118
O	817	818	)
O	818	819	.

O	820	823	All
O	824	832	patients
O	833	841	received
O	842	844	up
O	845	847	to
O	848	849	6
O	850	856	cycles
O	857	859	of
O	860	869	docetaxel
O	869	870	/
O	870	881	doxorubicin
O	882	894	chemotherapy
O	895	906	combination
O	907	910	and
O	911	912	a
O	913	917	once
O	917	918	-
O	918	921	per
O	921	922	-
O	922	927	cycle
O	928	937	injection
O	938	940	of
O	941	942	a
O	943	948	fixed
O	949	950	6
O	951	953	mg
O	954	958	dose
O	959	961	of
O	962	975	pegfilgrastim
O	975	976	.

O	977	984	Primary
O	985	993	endpoint
O	994	997	was
O	998	1001	the
B-outcome-Measure	1002	1010	duration
I-outcome-Measure	1011	1013	of
I-outcome-Measure	1014	1020	severe
I-outcome-Measure	1021	1032	neutropenia
I-outcome-Measure	1033	1034	(
I-outcome-Measure	1034	1037	ANC
I-outcome-Measure	1038	1039	<
I-outcome-Measure	1040	1041	0
I-outcome-Measure	1041	1042	.
I-outcome-Measure	1042	1043	5
I-outcome-Measure	1044	1045	×
I-outcome-Measure	1046	1049	109
I-outcome-Measure	1049	1050	/
I-outcome-Measure	1050	1051	L
I-outcome-Measure	1051	1052	)
I-outcome-Measure	1053	1055	in
I-outcome-Measure	1056	1061	Cycle
I-outcome-Measure	1062	1063	1
O	1064	1065	(
O	1065	1066	2
O	1066	1067	-
O	1067	1072	sided
O	1073	1075	CI
O	1076	1078	95
O	1078	1079	%
O	1079	1080	)
O	1080	1081	.

O	1082	1091	Secondary
O	1092	1101	endpoints
O	1102	1110	included
O	1111	1120	incidence
O	1121	1124	and
O	1125	1133	duration
O	1134	1136	of
O	1137	1143	severe
O	1144	1155	neutropenia
O	1156	1157	(
O	1157	1159	in
O	1160	1166	cycles
O	1167	1168	2
O	1168	1169	-
O	1169	1170	4
O	1170	1171	)
O	1171	1172	,
B-outcome-Measure	1173	1182	incidence
I-outcome-Measure	1183	1185	of
I-outcome-Measure	1186	1193	febrile
I-outcome-Measure	1194	1205	neutropenia
O	1205	1206	,
B-outcome-Measure	1207	1211	time
I-outcome-Measure	1212	1214	to
I-outcome-Measure	1215	1218	ANC
I-outcome-Measure	1219	1227	recovery
O	1227	1228	,
B-outcome-Measure	1229	1234	depth
I-outcome-Measure	1235	1237	of
I-outcome-Measure	1238	1241	ANC
I-outcome-Measure	1242	1247	nadir
I-outcome-Measure	1247	1248	,
O	1249	1252	and
B-outcome-Measure	1253	1259	safety
I-outcome-Measure	1260	1268	outcomes
O	1268	1269	.

O	1270	1273	The
B-outcome	1274	1278	mean
I-outcome	1279	1287	duration
I-outcome	1288	1290	of
I-outcome	1291	1297	severe
I-outcome	1298	1309	neutropenia
I-outcome	1310	1312	in
I-outcome	1313	1318	Cycle
I-outcome	1319	1320	1
O	1321	1324	was
B-iv-cont-mean	1325	1326	1
I-iv-cont-mean	1326	1327	.
I-iv-cont-mean	1327	1328	7
O	1329	1330	(
O	1330	1333	RGB
O	1333	1334	-
O	1334	1336	02
O	1336	1337	)
O	1338	1341	and
B-cv-cont-mean	1342	1343	1
I-cv-cont-mean	1343	1344	.
I-cv-cont-mean	1344	1345	6
I-cv-cont-mean	1346	1350	days
O	1351	1352	(
O	1352	1361	reference
O	1361	1362	)
O	1362	1363	,
O	1364	1368	with
O	1369	1370	a
O	1371	1381	difference
O	1382	1383	(
O	1383	1385	LS
O	1386	1390	Mean
O	1390	1391	)
O	1392	1394	of
O	1395	1396	0
O	1396	1397	.
O	1397	1398	1
O	1399	1403	days
O	1404	1405	(
O	1405	1407	95
O	1407	1408	%
O	1409	1411	CI
O	1412	1413	-
O	1413	1414	0
O	1414	1415	.
O	1415	1416	2
O	1416	1417	,
O	1418	1419	0
O	1419	1420	.
O	1420	1421	4
O	1421	1422	)
O	1422	1423	.

O	1424	1435	Equivalence
O	1436	1441	could
O	1442	1444	be
O	1445	1456	established
O	1457	1459	as
O	1460	1463	the
O	1464	1466	CI
O	1467	1470	for
O	1471	1474	the
O	1475	1485	difference
O	1486	1488	in
O	1489	1491	LS
O	1492	1496	Mean
O	1497	1500	lay
O	1501	1509	entirely
O	1510	1516	within
O	1517	1520	the
O	1521	1524	pre
O	1524	1525	-
O	1525	1532	defined
O	1533	1538	range
O	1539	1541	of
O	1542	1543	±
O	1543	1544	1
O	1545	1548	day
O	1548	1549	.

O	1550	1554	This
O	1555	1563	positive
O	1564	1570	result
O	1571	1574	was
O	1575	1584	supported
O	1585	1587	by
O	1588	1591	the
O	1592	1600	analysis
O	1601	1603	of
O	1604	1613	secondary
O	1614	1623	endpoints
O	1623	1624	,
O	1625	1630	which
O	1631	1635	also
O	1636	1644	revealed
O	1645	1647	no
O	1648	1656	clinical
O	1657	1667	meaningful
O	1668	1679	differences
O	1679	1680	.

B-outcome	1681	1687	Safety
I-outcome	1688	1696	profiles
O	1697	1701	were
O	1702	1712	comparable
O	1713	1720	between
O	1721	1727	groups
O	1727	1728	.

O	1729	1731	No
O	1732	1744	neutralizing
O	1745	1755	antibodies
O	1756	1763	against
O	1764	1777	pegfilgrastim
O	1778	1782	were
O	1783	1793	identified
O	1793	1794	.

O	1795	1804	Treatment
O	1805	1816	equivalence
O	1817	1819	in
O	1820	1828	reducing
O	1829	1832	the
O	1833	1841	duration
O	1842	1844	of
O	1845	1857	chemotherapy
O	1858	1865	induced
O	1866	1877	neutropenia
O	1878	1885	between
O	1886	1889	RGB
O	1889	1890	-
O	1890	1892	02
O	1893	1896	and
O	1897	1905	Neulasta
O	1905	1906	®
O	1907	1912	could
O	1913	1915	be
O	1916	1928	demonstrated
O	1928	1929	.

O	1930	1937	Similar
O	1938	1946	efficacy
O	1947	1950	and
O	1951	1957	safety
O	1958	1966	profiles
O	1967	1969	of
O	1970	1973	the
O	1974	1978	once
O	1978	1979	-
O	1979	1982	per
O	1982	1983	-
O	1983	1988	cycle
O	1989	2003	administration
O	2004	2006	of
O	2007	2010	RGB
O	2010	2011	-
O	2011	2013	02
O	2014	2017	and
O	2018	2021	the
O	2022	2035	pegfilgrastim
O	2036	2045	reference
O	2046	2050	were
O	2051	2063	demonstrated
O	2063	2064	.

O	2065	2068	The
O	2069	2074	trial
O	2075	2078	was
O	2079	2089	registered
O	2090	2103	prospectively
O	2103	2104	,
O	2105	2110	prior
O	2111	2113	to
O	2114	2119	study
O	2120	2130	initiation
O	2130	2131	.

O	2132	2139	EudraCT
O	2140	2146	number
O	2147	2148	(
O	2149	2153	2013
O	2153	2154	-
O	2154	2160	003166
O	2160	2161	-
O	2161	2163	14
O	2164	2165	)
O	2165	2166	.

O	2167	2170	The
O	2171	2175	date
O	2176	2178	of
O	2179	2191	registration
O	2192	2195	was
O	2196	2198	12
O	2199	2203	July
O	2203	2204	,
O	2205	2209	2013
O	2209	2210	.
